Genocea Biosciences to Highlight GEN-003 Clinical Data at the 42nd Annual International Herpesvirus Workshop
July 28 2017 - 8:00AM
- Pre-Conference symposium, posters, and oral
presentation will highlight GEN-003 Phase 2b clinical data -
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical
company developing novel vaccines and immunotherapies targeting T
cell antigens, announced today upcoming presentations at the 42nd
Annual International Herpesvirus Workshop taking place from July
29th through August 2nd in Ghent, Belgium.
Genocea scientists will be making the following presentations
during the conference:
“GEN-003, a Genital Herpes Immunotherapy, Showed
Significant Reduction in Viral Shedding and Lesion Rates in a Phase
2b Study Interim Analysis”
- Poster 8.25: Sunday, July 30th from 5:30 to 7 pm CEST (Poster
Session I)
“GEN-003 Immunotherapy Significantly Reduced the Viral
Shedding Rate in a Phase 2b Genital Herpes Clinical
Trial”
- Poster 8.31: Sunday, July 30th from 5:30 to 7 pm CEST (Poster
Session I)
“GEN-003, a herpes simplex virus immunotherapy, elicits
significant neutralizing antibody and cellular responses in HSV-2
seropositive subjects”
- Poster 8.04: Tuesday, August 1st from 5:30 to 7 pm CEST (Poster
Session II)
- Oral Presentation: Wednesday, August 2nd at 11:39 am CEST
“Reducing Variability of High-Throughput Herpes Simplex
Virus Neutralization Assays by Utilizing an Assay-Ready Cell Line
and Overlay Techniques”
- Pre-Conference Workshop on Saturday, July 29th
- Poster 1.22: Tuesday, August 1st from 5:30 to 7 pm CEST (Poster
Session II)
About GEN-003Inducing a T cell response against
genital herpes is critical to treating the clinical symptoms of
disease and controlling transmission of the infection. GEN-003 is a
first-in-class investigational T cell-directed immunotherapy
designed to elicit both a T cell and B cell (antibody) immune
response. The immunotherapy was designed using Genocea's ATLAS™
platform, which profiles the comprehensive spectrum of actual T
cell responses mounted by humans in response to disease and
identifies antigen targets that drive effective T cell responses.
GEN-003 includes the antigens ICP4 and gD2 along with Matrix-M™
adjuvant (licensed from Novavax, Inc. (NASDAQ:NVAX)). For more
information about GEN-003, please visit the GEN-003 section of the
Genocea website.
About Genital HerpesGenital Herpes affects more
than 400 million people worldwide and causes recurrent, painful
genital lesions. It can be transmitted to sexual partners, even
when the disease is asymptomatic. Current genital herpes therapies
only partially control clinical symptoms and viral shedding, a
process which drives disease transmission. Incomplete control of
genital lesions and transmission risk, expense and the perceived
inconvenience of taking a daily medication are hurdles for
long-term disease management. Immunity through T cells is believed
to be particularly critical to the control and possible prevention
of genital herpes infections.
About Genocea Biosciences, Inc.Genocea is
harnessing the power of T cell immunity to develop life-changing
vaccines and immunotherapies. While traditional immunotherapy
discovery methods have largely used predictive methods to propose T
cell targets, or antigens, Genocea has successfully developed
ATLAS™, its proprietary technology platform, to identify clinically
relevant antigens of T cells based on actual human immune
responses. Genocea used ATLAS to identify the antigens in its lead
clinical candidate, GEN-003, an investigational immunotherapy to
treat genital herpes, and is currently using ATLAS in
immuno-oncology applications to develop neoantigen cancer vaccines
(with an IND filing expected by the end of 2017), general cancer
vaccines and a vaccine targeting cancers caused by Epstein-Barr
Virus. For more information, please visit www.genocea.com.
Forward-Looking StatementsStatements herein
relating to future business performance, conditions or strategies
and other financial and business matters, including expectations
regarding clinical developments, are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act.
Genocea cautions that these forward-looking statements are subject
to numerous assumptions, risks, and uncertainties that change over
time. Factors that may cause actual results to differ materially
from the results discussed in the forward-looking statements or
historical experience include risks and uncertainties, including
Genocea's ability to progress any product candidates in preclinical
or clinical trials; the ability of ATLAS to identify promising
oncology vaccine and immunotherapy product candidates; the scope,
rate and progress of its preclinical studies and clinical trials
and other research and development activities; anticipated clinical
trial results; anticipated timing for initiation of new clinical
trials; current results may not be predictive of future results;
even if the data from preclinical studies or clinical trials is
positive, regulatory authorities may require additional studies for
approval and the product may not prove to be safe and efficacious;
Genocea's ability to enter into future collaborations with industry
partners and the government and the terms, timing and success of
any such collaboration; risks associated with the manufacture and
supply of clinical and commercial product; the cost of filing,
prosecuting, defending and enforcing any patent claims and other
intellectual property rights; Genocea's ability to obtain rights to
technology; competition for clinical resources and patient
enrollment from drug candidates in development by other companies
with greater resources and visibility; the rate of cash utilized by
Genocea in its business and the period for which existing cash will
be able to fund such operation; Genocea's ability to obtain
adequate financing in the future to continue its clinical programs
through product licensing, co-promotional arrangements, public or
private equity or debt financing or otherwise; general business
conditions; competition; business abilities and judgment of
personnel; the availability of qualified personnel and other
factors set forth under "Risk Factors" in Genocea's Annual Report
on Form 10-K for the fiscal year ended December 31, 2016 and other
filings with the Securities and Exchange Commission (the "SEC").
Further information on the factors and risks that could affect
Genocea's business, financial conditions, and results of operations
is contained in Genocea's filings with the SEC, which are available
at www.sec.gov. These forward-looking statements speak only as of
the date of this press release and Genocea assumes no duty to
update forward-looking statements.
For media:
Jennifer LaVin
207-360-0473
jennifer.lavin@genocea.com
For investors:
Jonathan Poole
617-876-8191
jonathan.poole@genocea.com
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Apr 2023 to Apr 2024